Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04802733
Other study ID # MSK-DA01-101
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date May 3, 2021
Est. completion date May 2024

Study information

Verified date May 2022
Source BlueRock Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial is designed to test whether surgically injecting nerve cells that make dopamine into the brain of Parkinson's disease patients is safe, and to monitor for potential side effects.


Description:

Subjects will undergo surgical transplantation of the dopamine-producing cells under general anesthesia into a part of the brain called the putamen. Subjects then take medicines to partially suppress their immune system (aimed to prevent the body from rejecting the cells) for 1 year. Safety, tolerability, evidence of cell survival (using MRI and PET scans of the brain), and effect on Parkinson's disease symptoms are assessed for 2 years post-transplant.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 12
Est. completion date May 2024
Est. primary completion date May 2023
Accepts healthy volunteers No
Gender All
Age group 50 Years to 78 Years
Eligibility Inclusion Criteria: - Age 50-78 years old (Canada) - Age 60-78 years old (United States) - Diagnosis of Parkinson's Disease made between 3 to 20 years ago - Taking levodopa, but with complications of therapy such as wearing off and/or dyskinesia - Able to participate in all study visits and evaluations, including brain MRI and PET scan - Existence of a study partner who may act as potential surrogate over long term for ongoing consent Exclusion Criteria: - Diagnosis of primary mitochondrial disorder, epilepsy, stroke, multiple sclerosis or other neurodegenerative diseases such as Alzheimer's disease - Prior Deep Brain Stimulation , lesion therapy, or gene therapy for PD - Prior surgical or radiation therapy to the brain or spinal cord - Any medical condition resulting in high risk of immunosuppressive drugs, including any active infectious disease - Inability to temporarily stop anti-platelet agents or other anti-coagulant medications without serious risk - Previous or currently active malignant disease within the past 5 years, except basal cell carcinoma or in situ uterine cervical carcinoma that have been treated - Severe obesity (>350 lbs) or any condition that prevents use of PET/MRI - Pregnancy or breastfeeding - Contraindication to surgery or general anesthesia - In the opinion of the investigator, any other condition regarded as making subject unsuitable for trial

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
MSK-DA01
MSK-DA01 is an experimental product derived from human embryonic stem cells. The stem cells were converted into brain cells that produce dopamine.
Device:
MSK-DA01 Cell Delivery Device
A device that is used for injection of fluids into the brain will be used. Some minor modifications have been made to the device to allow delivery of MSK-DA01 cells.

Locations

Country Name City State
Canada Toronto Western Hospital Toronto Ontario
United States Weill Cornell Medical College New York New York
United States University of California Irvine Orange California

Sponsors (2)

Lead Sponsor Collaborator
BlueRock Therapeutics Memorial Sloan Kettering Cancer Center

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and Tolerability The incidence of Serious Adverse Events (SAEs) at 1 year post-transplant. or abnormal tissue overgrowth related to presence of transplanted cells; Baseline to 1 Year Post-Transplant
Secondary Evidence of Cell Survival Change in 18F-DOPA uptake using positron emission tomography (PET) from baseline to 1 and 2 years Baseline to 1 Year Post-Transplant and Baseline to 2 Years Post-Transplant
Secondary Changes in Motor Function Changes in MDS-Unified Parkinson's Disease Rating Scale (UPDRS) motor sub-score in the "off" state from baseline to 2 years post-transplant. Baseline to 1 Year Post-Transplant and Baseline to 2 Years Post-Transplant
Secondary Changes in Waking Hours in "Off" State Changes in number of waking hours in the "off" state from baseline to 2 years post-transplant. Baseline to 1 Year Post-Transplant and Baseline to 2 Years Post-Transplant
Secondary Continued Safety and Tolerability Incidence of SAEs at 2 years post-transplant and incidence and type of AEs at 1 and 2 years post-transplant. Baseline to 1 Year Post-Transplant and Baseline to 2 Years Post-Transplant
See also
  Status Clinical Trial Phase
Recruiting NCT02154724 - Clinical Study for Adaptive Deep Brain Stimulation (aDBS)Controlled by Intracerebral Activity in Parkinson's Disease N/A
Completed NCT02549092 - A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD) Phase 3
Completed NCT01960842 - A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications Phase 3
Completed NCT01723904 - A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease Phase 3
Completed NCT01479127 - Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease Phase 2
Completed NCT03007888 - A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease Phase 2
Completed NCT00660673 - Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease Phase 3
Completed NCT01736176 - A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease Phase 3
Completed NCT02082249 - An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications Phase 3
Completed NCT02611713 - Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease
Terminated NCT01536015 - Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction Phase 3
Completed NCT00357994 - Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Phase 3
Completed NCT00335153 - Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease Phase 3
Active, not recruiting NCT06396494 - An Automated Navigation System for Deep Brain Electrode Implantation
Recruiting NCT06195124 - A Study on the Safety and Tolerability of RGL-193 in Patients With Advanced Parkinson's Disease Early Phase 1
Completed NCT00660387 - Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Phase 3